# Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

> **NCT06050122** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sol-Gel Technologies, Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Gorlin Syndrome

## Interventions

- **DRUG:** Patidegib Topical Gel
- **DRUG:** Patidegib Topical Gel with no active patidegib

## Key facts

- **NCT ID:** NCT06050122
- **Lead sponsor:** Sol-Gel Technologies, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-17
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06050122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06050122, "Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06050122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*